A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naive Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)
Latest Information Update: 02 May 2024
At a glance
- Drugs Radium 223 chloride (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ERA223
- Sponsors Bayer
- 01 Mar 2024 Status changed from active, no longer recruiting to completed.
- 02 Feb 2024 This trial has been Completed in Finland, According to European Clinical Trials Database record.
- 25 Jan 2024 This trial has been completed in France.